Cell signaling in cancer: From mechanisms to therapy
Bethesda, MD – This SRC focuses on understanding the molecular and cellular mechanisms of signaling in cancer in order to develop effective therapies. Specifically, the driving force behind this meeting is that understanding cancer at the molecular and cellular level opens the arena for novel therapeutic strategies. The meeting will cover cancer from the biochemical to the therapeutic level. Focus on genomics, spatial aspects of signaling, and patient data will be a new strength of the meeting, which formerly focused on lipid signaling in cancer. This conference broadens the mechanistic/biochemical aspect historically represented at the meeting to cover all signaling pathways relevant to developing therapies for cancer. The conference will provide ample opportunities for informal interaction to foster collaboration and promote the exchange of ideas.
FASEB has announced a total of 36 Science Research Conferences (SRC) in 2016. Registration opens January 17, 2016. For more information about an SRC, view preliminary programs, or find a listing of all our 2016 SRCs, please visit http://www.faseb.org/SRC.
Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes. In efforts to expand the SRC series, potential organizers are encouraged to contact SRC staff at [email protected] Proposal guidelines can be found at http://www.faseb.org/SRC.
FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.